We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

17 hedge funds and large institutions have $2.63M invested in Decoy Therapeutics in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

15% less funds holding

Funds holding: 20 → 17 (-3)

62% less capital invested

Capital invested by funds: $6.84M → $2.63M (-$4.21M)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$265K
2
Renaissance Technologies
Renaissance Technologies
New York
+$132K
3
Two Sigma Investments
Two Sigma Investments
New York
+$52.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$26.5K

Top Sellers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
-$1.24M
2
Morgan Stanley
Morgan Stanley
New York
-$556K
3
MIH
Meitav Investment House
Israel
-$53K
4
VF
Virtu Financial
New York
-$30K
5
FAIM
Financial Advocates Investment Management
Washington
-$12K

DCOY Hedge Fund Activity: Q4 2021 in Review

17 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2021, worth a combined $2.63M — down 62% from $6.84M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of DCOY and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Two Sigma Advisers, adding an estimated $265K. The largest seller was Maven Securities, exiting entirely with an estimated $1.24M sold.

  • 17 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2021, down from 20 in Q3 2021.
  • Funds reported $2.63M of Decoy Therapeutics stock for Q4 2021, down 62% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q4 2021 and 4 closed out, a net change of -3 holders.
  • The largest Decoy Therapeutics buyer in Q4 2021 was Two Sigma Advisers, an estimated $265K added.
  • The largest Decoy Therapeutics seller in Q4 2021 was Maven Securities, an estimated $1.24M sold.

Based on aggregated 13F filings for Q4 2021.